<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Although several viruses can easily infect the" exact="central nervous system" post="(CNS), antiviral drugs often show dramatic difficulties in penetrating"/>
 <result pre="(ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and" exact="breast cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
 <result pre="or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast" exact="cancer" post="resistance protein (ABCG2 or BCRP). Inhibitors of AETs may"/>
 <result pre="interesting substrates for innovative nasal formulations able to target anti-Human" exact="Immunodeficiency" post="Virus (HIV) agents into macrophages of the CNS, which"/>
 <result pre="Virus (CDV) and Measles Virus (MV) are known to cause" exact="demyelinating disease" post="of the central nervous system (CNS) in dogs and"/>
 <result pre="(CDV) and Measles Virus (MV) are known to cause demyelinating" exact="disease" post="of the central nervous system (CNS) in dogs and"/>
 <result pre="Virus (MV) are known to cause demyelinating disease of the" exact="central nervous system" post="(CNS) in dogs and humans, respectively; and Eastern Equine"/>
 <result pre="nervous system (CNS) in dogs and humans, respectively; and Eastern" exact="Equine" post="Encephalitis Virus (EEEV) is able to induce death or"/>
 <result pre="system (CNS) in dogs and humans, respectively; and Eastern Equine" exact="Encephalitis" post="Virus (EEEV) is able to induce death or long-lasting"/>
 <result pre="be lethal within the brain [2,3,4]; moreover, Herpes Simplex Virus" exact="type 1" post="(HSV-1) can cause potentially fatal encephalitis in developed countries"/>
 <result pre="Herpes Simplex Virus type 1 (HSV-1) can cause potentially fatal" exact="encephalitis" post="in developed countries [5,6]. Finally, mice intra-nasally infected by"/>
 <result pre="in developed countries [5,6]. Finally, mice intra-nasally infected by Venezuelan" exact="Equine" post="Encephalitis Virus (VEEV) show a CNS phase that results"/>
 <result pre="developed countries [5,6]. Finally, mice intra-nasally infected by Venezuelan Equine" exact="Encephalitis" post="Virus (VEEV) show a CNS phase that results in"/>
 <result pre="Encephalitis Virus (VEEV) show a CNS phase that results in" exact="encephalitis" post="and death [7,8,9]. Human Immunodeficiency Virus type-1 (HIV-1) belongs"/>
 <result pre="CNS phase that results in encephalitis and death [7,8,9]. Human" exact="Immunodeficiency" post="Virus type-1 (HIV-1) belongs to the lentivirus family. It"/>
 <result pre="It displays a long latency period and a slow progressive" exact="disease" post="culminating in severe immune deficiencies together called acquired immune"/>
 <result pre="slow progressive disease culminating in severe immune deficiencies together called" exact="acquired" post="immune deficiency syndrome (AIDS) [10]. The virus firstly infects"/>
 <result pre="disease culminating in severe immune deficiencies together called acquired immune" exact="deficiency" post="syndrome (AIDS) [10]. The virus firstly infects CD4+ T"/>
 <result pre="culminating in severe immune deficiencies together called acquired immune deficiency" exact="syndrome" post="(AIDS) [10]. The virus firstly infects CD4+ T lymphocytes,"/>
 <result pre="The presence of HIV in the brain can lead to" exact="dementia" post="in the more severe cases [13,14]. The CNS therefore"/>
 <result pre="the treatment of AIDS and that their administration dramatically reduces" exact="viral" post="loads in HIV patients, the eradication of the virus"/>
 <result pre="can cause severe side effects, such as lipodystrophy, diabetes, and" exact="cardiovascular disease" post="[21]. 2. Active Efflux Transporters Do Not Allow the"/>
 <result pre="cause severe side effects, such as lipodystrophy, diabetes, and cardiovascular" exact="disease" post="[21]. 2. Active Efflux Transporters Do Not Allow the"/>
 <result pre="and The solute carrier (SLC) gene family of energy-independent or" exact="secondary" post="active efflux transporters. As far as antiretroviral drugs are"/>
 <result pre="it has recently been reported that the concomitant exposition of" exact="primary" post="human brain microvascular endothelial cells (HBMVEC) to HIV-1 and"/>
 <result pre="further restriction to the entry of antiretroviral drugs to the" exact="central nervous system." post="The induction of P-gp in peripheral organs and brain"/>
 <result pre="to the central nervous system. The induction of P-gp in" exact="peripheral" post="organs and brain microvessel endothelial cells appears to be"/>
 <result pre="valspodar), which were characterized by higher inhibitory activity and the" exact="absence of" post="therapeutic targets other than the targeted transporters. However, also"/>
 <result pre="laniquidar), which was characterized by very high potency and the" exact="absence of" post="drug metabolic interactions, was not confirmed as being deprived"/>
 <result pre="perspectives for the selective target of their action within the" exact="central nervous system" post="[28]. Knowledge of the structure–activity relationships (SAR) of ABC"/>
 <result pre="selective targeting of the prodrugs may be obtained in the" exact="central nervous system" post="where it seems reasonable to hypothesize they can easily"/>
 <result pre="transporters whose AZT is a substrate in cell monolayers showing" exact="epithelial" post="barrier features [71]. In particular, this type of prodrug"/>
 <result pre="used as innovative formulations to target the prodrug in the" exact="central nervous system" post="following their nasal administration. The aspects regarding brain targeting"/>
 <result pre="Can These Innovative Formulations Target the Antiviral Drugs in the" exact="Central Nervous System?" post="Bearing in mind that monocytes and macrophages can act"/>
 <result pre="These Innovative Formulations Target the Antiviral Drugs in the Central" exact="Nervous System?" post="Bearing in mind that monocytes and macrophages can act"/>
 <result pre="proposed in order to carry the antiretroviral drugs to the" exact="central nervous system" post="[74]. In particular, the idea of formulating nanoparticles loaded"/>
 <result pre="Administration: A Promising Strategy for Antiviral Drug Uptake in the" exact="Brain" post="Receptor-mediated transportation, transporter-mediated transport, adsorptive-mediated transportation, or temporarily increased"/>
 <result pre="order to obtain the uptake of antiviral drugs in the" exact="central nervous system," post="the nasal approach would appear to be a promising"/>
 <result pre="paracellular or transcellular transport via the olfactory neurones or olfactory" exact="epithelial" post="cells); (ii) the trigeminal pathway (transport via trigeminal nerves);"/>
 <result pre="the trigeminal pathway (transport via trigeminal nerves); and (iii) the" exact="systemic" post="pathway (the drug is absorbed into the bloodstream, then"/>
 <result pre="the poorest chances of allowing antiviral drugs access to the" exact="central nervous system," post="since most of them are substrates of the AET"/>
 <result pre="an extracellular route without binding to any receptor or undergoing" exact="axonal" post="transport [82]. Some drugs can be axonally transported into"/>
 <result pre="structures); the trigeminal pathway allows for drug distribution in the" exact="upper" post="cervical spinal cord, midbrain, pons, and hypothalamus (caudal brain"/>
 <result pre="brain structures) [79]. The efficacy of nasal administration against neurotropic" exact="viral" post="effects was tested on mice infected by herpes simplex"/>
 <result pre="against neurotropic viral effects was tested on mice infected by" exact="herpes" post="simplex virus type 1 (HSV-1). In particular, mice models"/>
 <result pre="effects was tested on mice infected by herpes simplex virus" exact="type 1" post="(HSV-1). In particular, mice models of HSV-1 encephalitis received"/>
 <result pre="virus type 1 (HSV-1). In particular, mice models of HSV-1" exact="encephalitis" post="received an intranasal pretreatment with the immunostimulant polyinosinic:polycytidylic acid"/>
 <result pre="canine distemper virus (CDV) and also indicated for treatment of" exact="hepatitis" post="C [84], allowed investigators to obtain drug concentrations in"/>
 <result pre="to increase the contact between the drug and olfactory nasal" exact="mucosa" post="may induce an enhancement of drug bioavailability in the"/>
 <result pre="that obtained by nasal administration of ribavirin-micronized powder in the" exact="absence of" post="α-cyclodextrin microparticles able to induce penetration-enhancing properties [86]. Appropriate"/>
 <result pre="in the nasal cavity and nose-to-brain delivery while overcoming unwanted" exact="pulmonary" post="distribution [88,89,90]. Concerning innovative devices for the nasal administration"/>
 <result pre="of nose drops in rats, which deposited primarily on the" exact="respiratory" post="region, or after deposition primarily on their olfactory region"/>
 <result pre="or on treatments against cold viruses acting outside of the" exact="central nervous system" post="[92]. Innovative formulations able to target antiviral drugs in"/>
 <result pre="mucoadhesive properties that enhance the adhesion of formulations onto nasal" exact="mucosa" post="[97] and drug bioavailability [98]. Thermoresponsive and mucoadhesive hydrogel"/>
 <result pre="is able to transiently open the tight junctions in the" exact="epithelial" post="cells [101]. These properties allow chitosan to prolong the"/>
 <result pre="papaverine appeared to be able to induce a rapid and" exact="transient" post="decrease in the tight junction protein-phosphorylated occludin in the"/>
 <result pre="a model drug) reaching the brain, which was explained by" exact="transient" post="dephosphorylation of occludin following disassembly of the tight junctions"/>
 <result pre="the cytoplasm of mucosal cells [105]. 8.3. Nasal Formulations and" exact="Brain" post="Targeting of Antiviral Drugs New nasal formulations of antiviral"/>
 <result pre="in vivo in order to evaluate drug absorption in the" exact="central nervous system." post="Among these, an intranasal nano-emulsion based on the hydrophobic"/>
 <result pre="order to induce the uptake of zidovudine (AZT) in the" exact="central nervous system." post="It is well-known that AZT penetration in the CNS"/>
 <result pre="bloodstream and the CSF, even if the CSF/plasma ratio was" exact="lower" post="than 1 and weakly increased in the presence of"/>
 <result pre="in order to prolong its permanence upon targeting in the" exact="central nervous system" post="and to permeate in its macrophages where the AZT"/>
 <result pre="insulin treatment of HIV-infected microglia cultures induces a reduction in" exact="viral" post="replication as evidenced by the suppression of supernatant HIV-1"/>
 <result pre="and IL-6 transcript levels. Moreover, it has been demonstrated that" exact="primary" post="human neurons treated with insulin prevent HIV-1 Vpr-mediated cell"/>
 <result pre="process retraction and death. Bearing these aspects in mind, feline" exact="immunodeficiency" post="virus (FIV)-infected animals were treated by intranasal insulin and"/>
 <result pre="represent a new therapeutic option for patients affected by neurodegenerative" exact="syndrome" post="HIV-associated neurocognitive disorders. 9. Conclusions We have evidenced that"/>
 <result pre="We have evidenced that several viruses can easily infect the" exact="central nervous system," post="but even if numerous antiviral therapies can be efficacious"/>
 <result pre="but even if numerous antiviral therapies can be efficacious at" exact="peripheral" post="levels, they appear to be inefficacious at the central"/>
 <result pre="a consequent further reduction in the antiviral efficacy in the" exact="central nervous system." post="In order to counteract this phenomenon, the use of"/>
 <result pre="to target the antiviral drugs or their prodrugs in the" exact="central nervous system." post="The results obtained from these studies indicate that the"/>
 <result pre="means to promote the efficacy of antiviral therapies against the" exact="neurotoxicity" post="of viruses. Acknowledgments Support from the University of Ferrara"/>
 <result pre="United States and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular" exact="stomatitis" post="virus infection of immunodeficient miceJ. Virol.199367669867068105106 3.Van den PolA.N.DaltonK.P.RoseJ.K.Relative"/>
 <result pre="States and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular stomatitis" exact="virus infection" post="of immunodeficient miceJ. Virol.199367669867068105106 3.Van den PolA.N.DaltonK.P.RoseJ.K.Relative neurotropism of"/>
 <result pre="and CanadaClin. Microbiol. Rev.199478911610.1128/CMR.7.1.898118792 2.HuneycuttB.S.BiZ.AokiC.J.ReissC.S.Central neuropathogenesis of vesicular stomatitis virus" exact="infection" post="of immunodeficient miceJ. Virol.199367669867068105106 3.Van den PolA.N.DaltonK.P.RoseJ.K.Relative neurotropism of"/>
 <result pre="fluorescent envelope glycoproteinJ. Virol.2002761309132710.1128/JVI.76.3.1309-1327.200211773406 4.Van den PolA.N.DavisJ.N.Highly attenuated recombinant vesicular" exact="stomatitis" post="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update"/>
 <result pre="virus VSV-12’GFP displays immunogenic and oncolytic activityJ. Virol.2013871019103410.1128/JVI.01106-1223135719 5.TylerK.L.Update on" exact="herpes" post="simplex encephalitisRev. Neurol. Dis.2004116917816400278 6.WhitleyR.J.KimberlinD.W.Herpes simplex encephalitis: Children and"/>
 <result pre="arising in vivo define early steps in the pathogenesis of" exact="Venezuelan equine encephalitis" post="virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine encephalitis"/>
 <result pre="vivo define early steps in the pathogenesis of Venezuelan equine" exact="encephalitis" post="virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine encephalitis"/>
 <result pre="of Venezuelan equine encephalitis virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of" exact="Venezuelan equine encephalitis" post="virus-induced disease in the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach"/>
 <result pre="equine encephalitis virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine" exact="encephalitis" post="virus-induced disease in the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach"/>
 <result pre="virusVirology200027011112310.1006/viro.2000.024110772984 8.CharlesP.C.TrgovcichJ.DavisN.L.JohnstonR.E.Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced" exact="disease" post="in the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the"/>
 <result pre="the mouseVirology200128419020210.1006/viro.2001.087811384219 9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the study of" exact="Venezuelan equine encephalitis" post="virus pathogenesisArch. Virol. Suppl.19949991098032286 10.PomerantzR.J.Reservoirs, sanctuaries and residual disease:"/>
 <result pre="9.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the study of Venezuelan equine" exact="encephalitis" post="virus pathogenesisArch. Virol. Suppl.19949991098032286 10.PomerantzR.J.Reservoirs, sanctuaries and residual disease:"/>
 <result pre="disease: The hiding spots of HIV-1HIV Clin. Trials2003413714310.1310/hct.2003.4.2.00912671782 11.LambotteO.DeivaK.TardieuM.HIV-1 persistence," exact="viral" post="reservoir and the central nervous system in the HAART"/>
 <result pre="of HIV-1HIV Clin. Trials2003413714310.1310/hct.2003.4.2.00912671782 11.LambotteO.DeivaK.TardieuM.HIV-1 persistence, viral reservoir and the" exact="central nervous system" post="in the HAART eraBrain Pathol.2003139510310.1111/j.1750-3639.2003.tb00010.x12580549 12.AquaroS.SvicherV.ScholsD.PollicitaM.AntinoriA.BalzariniJ.PernoC.F.Mechanisms underlying activity of"/>
 <result pre="therapeutic strategiesJ. Leukoc. Biol.2006801103111010.1189/jlb.060637616931601 13.KaulM.HIV’s double strike at the brain:" exact="Neuronal" post="toxicity and compromised neurogenesisFront. Biosci.2008132484249410.2741/286017981728 14.KolsonD.L.Gonzalez-ScaranoF.HIV and HIV dementiaJ."/>
 <result pre="CXCR4 coreceptors—Central to understanding the transmission and pathogenesis of human" exact="immunodeficiency" post="virus type 1 infectionAIDS Res. Hum. Retroviruses20042011112610.1089/08892220432274956715000703 19.DorrP.WestbyM.DobbsS.GriffinP.IrvineB.MacartneyM.MoriJ.RickettG.Smith-BurchnellC.NapierC.et al.Maraviroc"/>
 <result pre="to understanding the transmission and pathogenesis of human immunodeficiency virus" exact="type 1" post="infectionAIDS Res. Hum. Retroviruses20042011112610.1089/08892220432274956715000703 19.DorrP.WestbyM.DobbsS.GriffinP.IrvineB.MacartneyM.MoriJ.RickettG.Smith-BurchnellC.NapierC.et al.Maraviroc (UK-427, 857), a"/>
 <result pre="selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human" exact="immunodeficiency" post="virus type 1 activityAntimicrob. Agents Chemother.2005494721473210.1128/AAC.49.11.4721-4732.200516251317 20.ReeseM.J.SavinaP.M.GenerauxG.T.TraceyH.HumphreysJ.E.KanaokaE.WebsterL.O.HarmonK.A.ClarkeJ.D.PolliJ.W.In vitro investigations"/>
 <result pre="inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus" exact="type 1" post="activityAntimicrob. Agents Chemother.2005494721473210.1128/AAC.49.11.4721-4732.200516251317 20.ReeseM.J.SavinaP.M.GenerauxG.T.TraceyH.HumphreysJ.E.KanaokaE.WebsterL.O.HarmonK.A.ClarkeJ.D.PolliJ.W.In vitro investigations into the roles"/>
 <result pre="22.ChaudharyP.M.MechetnerE.B.RoninsonI.B.Expression and activity of the multidrug resistance P-glycoprotein in human" exact="peripheral" post="blood lymphocytesBlood199280273527391360267 23.NeyfakhA.A.SerpinskayaA.S.ChervonskyA.V.ApasovS.G.KazarovA.R.Multidrug-resistance phenotype of a subpopulation of T-lymphocytes"/>
 <result pre="intracellular concentration of lopinavir in cultured CD4 T cells and" exact="primary" post="human lymphocytesJ. Antimicrob. Chemother.20076098799310.1093/jac/dkm35317890284 25.DalpiazA.FogagnoloM.FerraroL.CapuzzoA.PavanB.RassuG.SalisA.GiunchediP.GaviniE.Nasal chitosan microparticles target a"/>
 <result pre="eradicating HIV reservoirs in the brain: Inhibiting P-glycoprotein at the" exact="blood-brain barrier" post="with prodrug abacavir dimersJ. Am. Chem. Soc.20121342976298010.1021/ja206867t21866921 27.PavanB.DalpiazA.Prodrugs and"/>
 <result pre="into the central nervous system?Curr. Pharm. Des.2011173560357610.2174/13816121179819448622074427 28.PavanB.PaganettoG.RossiD.DalpiazA.Multidrug resistance in" exact="cancer" post="or inefficacy of neuroactive agents: Innovative strategies to inhibit"/>
 <result pre="protease inhibitors are inhibitors but not substrates of the human" exact="breast cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
 <result pre="inhibitors are inhibitors but not substrates of the human breast" exact="cancer" post="resistance protein (BCRP/ABCG2)J. Pharmacol. Exp. Ther.200431033434110.1124/jpet.104.06534215007102 35.RonaldsonP.T.LeeG.DallasS.BendayanR.Involvement of P-glycoprotein"/>
 <result pre="Pharm. Sci.20024E1410.1208/ps04031412423063 41.JannehO.OwenA.ChandlerB.HartkoornR.C.HartC.A.BrayP.G.WardS.A.BackD.J.KhooS.H.Modulation of the intracellular accumulation of saquinavir in" exact="peripheral" post="blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp"/>
 <result pre="46.WalkerD.K.BowersS.J.MitchellR.J.PotchoibaM.J.SchroederC.M.SmallH.F.Preclinical assessment of the distribution of maraviroc to potential human" exact="immunodeficiency" post="virus (HIV) sanctuary sites in the central nervous system"/>
 <result pre="to potential human immunodeficiency virus (HIV) sanctuary sites in the" exact="central nervous system" post="(CNS) and gut-associated lymphoid tissue (GALT)Xenobiotica2008381330133910.1080/0049825080244740918853388 47.RamanathanS.AbelS.TweedyS.WestS.HuiJ.KearneyB.P.Pharmacokinetic interaction of"/>
 <result pre="57.BauerB.YangX.HartzA.M.S.OlsonE.R.ZhaoR.KalvassJ.C.PollackG.M.MillerD.S.In vivo activation of human pregnane X receptor tightens the" exact="blood-brain barrier" post="to methadone through P-glycoprotein up-regulationMol. Pharmacol.2006701212121910.1124/mol.106.02379616837625 58.OttM.FrickerG.BauerB.Pregnane X receptor"/>
 <result pre="Pharmacol.20107837638310.1124/mol.110.06368520547735 60.LemmenJ.TozakidisI.E.P.BeleP.GallaH.J.Constitutive androstane receptor upregulates Abcb1 and Abcg2 at the" exact="blood-brain barrier" post="after CITCO activationBrain Res.20131501688010.1016/j.brainres.2013.01.02523340159 61.ChanG.N.HoqueM.T.CumminsC.L.BendayanR.Regulation of P-glycoprotein by orphan"/>
 <result pre="drugs in human brain microvessel endothelial cellsAntimicrob. Agents Chemother.2013574481448810.1128/AAC.00486-1323836171 65.ShuklaS.OhnumaS.AmbudkarS.V.Improving" exact="cancer" post="chemotherapy with modulators of ABC drug transportersCurr. Drug Targets20111262163010.2174/13894501179537854021039338"/>
 <result pre="genesBiochim. Biophys. Acta2007177523726210.1016/j.bbcan.2007.05.00217572300 67.XiaC.Q.SmithP.G.Drug efflux transporter and multidrug resistance in" exact="acute" post="leukemia: Therapeutic impact and novel approaches to mediationMol. Pharmacol.2012821008102110.1124/mol.112.07912922826468"/>
 <result pre="pretreatment with toll-like receptor agonists in a mouse model of" exact="herpes" post="simplex virus type 1 encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro"/>
 <result pre="receptor agonists in a mouse model of herpes simplex virus" exact="type 1" post="encephalitisJ. Infect. Dis.200819866467210.1086/59067118662130 84.EliaG.BelloliC.CironeF.LucenteM.S.CarusoM.MartellaV.DecaroN.BuonavogliaC.OrmasP.In vitro efficacy of ribavirin against"/>
 <result pre="for direct nose-to-brain delivery of drugsInt. J. Pharm.200937914615710.1016/j.ijpharm.2009.06.01919555750 88.HoekmanJ.D.HoR.J.Effects of" exact="localized" post="hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory"/>
 <result pre="carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′, 3′-dideoxyinosine across the" exact="blood-brain barrier" post="via a probenecid-sensitive transport systemJ. Pharmacol. Exp. Ther.19972813693759103519 110.WangY.SawchukR.J.Zidovudine"/>
 <result pre="specific regions in rabbit brain using microdialysisPharm. Res.1992933233810.1023/A:10158347011361614966 112.CunninghamA.L.NaifH.SaksenaN.LynchG.ChangJ.LiS.JozwiakR.AlaliM.WangB.FearW.et al.HIV" exact="infection" post="of macrophages and pathogenesis of AIDS dementia complex: Interaction"/>
 <result pre="Res.1992933233810.1023/A:10158347011361614966 112.CunninghamA.L.NaifH.SaksenaN.LynchG.ChangJ.LiS.JozwiakR.AlaliM.WangB.FearW.et al.HIV infection of macrophages and pathogenesis of AIDS" exact="dementia" post="complex: Interaction of the host cell and viral genotypeJ."/>
 <result pre="of AIDS dementia complex: Interaction of the host cell and" exact="viral" post="genotypeJ. Leukocyte Biol.19976211712510.1002/jlb.62.1.1179226002 113.Ghersi-EgeaJ.F.FinneganW.ChenJ.L.FenstermacherJ.D.Rapid distribution of intraventricularly administered sucrose"/>
 <result pre="dementia complex: Interaction of the host cell and viral genotypeJ." exact="Leukocyte" post="Biol.19976211712510.1002/jlb.62.1.1179226002 113.Ghersi-EgeaJ.F.FinneganW.ChenJ.L.FenstermacherJ.D.Rapid distribution of intraventricularly administered sucrose into cerebrospinal"/>
 <result pre="ratsPharm. Bull.1994171135113710.1248/bpb.17.1135 115.GillP.S.RarickM.BrynesR.K.CauseyD.LoureiroC.LevineA.Azidothymidine associated with bone marrow failure in the" exact="acquired" post="immunodeficiency syndrome (AIDS)Ann. Int. Med.198710750250510.7326/0003-4819-107-4-5023477107 116.VedP.M.KimK.Poly(ethylene oxide/propylene oxide) copolymer"/>
 <result pre="Bull.1994171135113710.1248/bpb.17.1135 115.GillP.S.RarickM.BrynesR.K.CauseyD.LoureiroC.LevineA.Azidothymidine associated with bone marrow failure in the acquired" exact="immunodeficiency" post="syndrome (AIDS)Ann. Int. Med.198710750250510.7326/0003-4819-107-4-5023477107 116.VedP.M.KimK.Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible"/>
 <result pre="115.GillP.S.RarickM.BrynesR.K.CauseyD.LoureiroC.LevineA.Azidothymidine associated with bone marrow failure in the acquired immunodeficiency" exact="syndrome" post="(AIDS)Ann. Int. Med.198710750250510.7326/0003-4819-107-4-5023477107 116.VedP.M.KimK.Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling"/>
 <result pre="of anti-HIV therapeutic agentsExpert Opin. Drug Deliv.20131097398510.1517/17425247.2013.78199923510097 118.MamikM.K.AsahchopE.L.ChanW.F.ZhuY.BrantonW.G.McKenzieB.A.CohenE.A.PowerC.Insulin treatment prevents" exact="neuroinflammation" post="and neuronal injury with restored neurobehavioral function in models"/>
 <result pre="therapeutic agentsExpert Opin. Drug Deliv.20131097398510.1517/17425247.2013.78199923510097 118.MamikM.K.AsahchopE.L.ChanW.F.ZhuY.BrantonW.G.McKenzieB.A.CohenE.A.PowerC.Insulin treatment prevents neuroinflammation and" exact="neuronal" post="injury with restored neurobehavioral function in models of HIV/AIDS"/>
 <result pre="and neuronal injury with restored neurobehavioral function in models of" exact="HIV/AIDS" post="neurodegenerationJ. Neurosci.201636106831069510.1523/JNEUROSCI.1287-16.201627733618 pharmaceutics-10-00039-t001_Table 1Table 1 The ATP-binding cassette (ABC)"/>
 <result pre="lopinavir, amprenavir, nelfinavir, indinavir, abacavir, dolutegravir cyclosporine-A, verapamil, mefloquine Multidrug" exact="Resistance" post="Protein MRP-1 ABCC1 hydrophilic anion compounds, large molecules saquinavir,"/>
 <result pre="amprenavir, nelfinavir, indinavir, abacavir, dolutegravir cyclosporine-A, verapamil, mefloquine Multidrug Resistance" exact="Protein" post="MRP-1 ABCC1 hydrophilic anion compounds, large molecules saquinavir, ritonavir,"/>
 <result pre="ABCC4 ABCC5 small polar compounds, nucleoside analogues Zidovudine, didanosine Breast-Cancer-Resistance" exact="Protein" post="BRCP ABCG2 partially overlap with those of P-gp zidovudine,"/>
</results>
